Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer

Tas,Faruk; Bilgin,Elif; Tastekin,Didem; Erturk,Kayhan; Duranyildiz,Derya

doi:10.3892/br.2016.629

May-2016 Volume 4 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2016 Volume 4 Issue 5

Full Size Image

Article

Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer

Authors:
- Faruk Tas
- Elif Bilgin
- Didem Tastekin
- Kayhan Erturk
- Derya Duranyildiz
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Institute of Oncology, University of Istanbul, Capa, Istanbul 34390, Turkey
Pages: 609-614
|
Published online on: March 9, 2016

https://doi.org/10.3892/br.2016.629
Expand metrics +

Abstract

Insulin-like growth factor-1 (IGF-1) and its essential binding protein-3 (IGFBP-3) exhibit significant roles in cellular proliferation, differentiation and apoptosis in numerous malignancies, including lung cancer. The aim of the present study was to determine the clinical roles of the serum IGF-1 and IGFBP-3 levels in lung cancer patients. A total of 80 patients with lung cancer were enrolled in the study. Serum IGF-1 and IGFBP-3 concentrations were determined by ELISA methods. The median age of patients was 58.5 years old, with a range of 36-80 years. The majority of the patients had non‑small cell lung cancer (NSCLC) (85%) and metastatic disease (56%). No significant differences were observed in serum IGF‑1 levels between lung cancer patients and healthy subjects (P=0.403). However, baseline serum IGFBP‑3 levels of the lung cancer patients were significantly lower compared to the control group (P<0.001). The male patients had elevated serum IGF‑1 concentrations compared to females (P=0.025). Furthermore, patients with NSCLC histology and metastatic stage in NSCLC had elevated serum IGF‑1 (P=0.022 and P=0.039, respectively) and IGFBP‑3 (P=0.005 and P=0.043, respectively) levels compared with those with SCLC histology and non‑metastatic stage in NSCLC. However, none of the other clinical variables, including age of patient, tumor histology and chemotherapy responsiveness, were observed as correlated with serum assays of IGF-1 and IGFBP-3 (P>0.05). There was a significant association found between IGF-1 and IGFBP-3 serum levels in lung cancer patients (P<0.001). Neither serum IGF‑1 nor IGFBP-3 concentrations were associated with outcome (P=0.552 and P=0.471, respectively). In conclusion, serum concentrations of IGFBP‑3 may have a diagnostic predictor in patients with lung cancer compared to serum IGF‑1 concentrations. However, predictive and prognostic values of the two serum assays were not observed.

View Figures

View References

1	Yu H, Spitz MR, Mistry J, Gu J, Hong WK and Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst. 91:151–156. 1999. View Article : Google Scholar : PubMed/NCBI
2	London SJ, Yuan JM, Travlos GS, Gao YT, Wilson RE, Ross RK and Yu MC: Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst. 94:749–754. 2002. View Article : Google Scholar : PubMed/NCBI
3	Chen B, Liu S, Xu W, Wang X, Zhao W and Wu J: IGF-I and IGFBP-3 and the risk of lung cancer: A meta-analysis based on nested case-control studies. J Exp Clin Cancer Res. 28:892009. View Article : Google Scholar : PubMed/NCBI
4	Cao H, Wang G, Meng L, Shen H, Feng Z, Liu Q and Du J: Association between circulating levels of IGF-1 and IGFBP-3 and lung cancer risk: A meta-analysis. PLoS One. 7:e498842012. View Article : Google Scholar : PubMed/NCBI
5	Lee DY, Kim SJ and Lee YC: Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci. 14:401–404. 1999. View Article : Google Scholar : PubMed/NCBI
6	Unsal E, Köksal D, Yurdakul AS, Atikcan S and Cinaz P: Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer. Respir Med. 99:559–565. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wang Z, Wang Z, Liang Z, Liu J, Shi W, Bai P, Lin X, Magaye R and Zhao J: Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancer. Onco Targets Ther. 6:1437–1444. 2013.PubMed/NCBI
8	Han JY, Choi BG, Choi JY, Lee SY and Ju SY: The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer. 54:227–234. 2006. View Article : Google Scholar : PubMed/NCBI
9	Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, et al: Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer. Oncol Rep. 26:795–803. 2011.PubMed/NCBI
10	Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
11	Detterbeck FC, Boffa DJ and Tanoue LT: The new lung cancer staging system. Chest. 136:260–271. 2009. View Article : Google Scholar : PubMed/NCBI
12	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles